Genetic prodrug activation therapy (GPAT) in two rat prostate models generates an immune bystander effect and can be monitored by magnetic resonance techniques

Gene Therapy

Volumn 8, Issue 7, 2001, Pages 557-567

  Eaton, J D ^a,b   Perry, M J A ^a,b   Todryk, S M ^a   Mazucco, R A ^a   Kirby, R S ^b   Griffiths, J R ^a   Dalgleish, A G ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

GPAT; Immunity; Prostate cancer; Suicide gene therapy

Indexed keywords

ADENOSINE TRIPHOSPHATE; GAMMA INTERFERON; GANCICLOVIR; LIPOCORTIN 5; PHOSPHATASE; PHOSPHATE; PRODRUG; THYMIDINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CELL CULTURE; CELL ENERGY; CELL KILLING; CONTROLLED STUDY; DRUG ACTIVATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; GENE THERAPY; GENETIC TRANSFECTION; HELPER CELL; HERPES SIMPLEX VIRUS; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS; MONITORING; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROSTATE CANCER; RAT; SPLEEN CELL; SUBCUTANEOUS TISSUE; SUICIDE GENE; TUMOR CELL; TUMOR CELL LINE; TUMOR GROWTH;

ANIMALS; APOPTOSIS; CELL SURVIVAL; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; GANCICLOVIR; GENE THERAPY; MAGNETIC RESONANCE SPECTROSCOPY; MALE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PRODRUGS; PROSTATIC NEOPLASMS; RATS; TH1 CELLS; THYMIDINE KINASE; TRANSFECTION; TUMOR CELLS, CULTURED;

ANIMALIA; HERPES; SIMPLEXVIRUS;

EID: 0035038479     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301432     Document Type: Article

References (39)

1. Gene therapy for prostate cancer
2. Cancer vaccines
3. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor transfer
4. Follow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides
5. Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants oflong-term prognosis in prostatic adenocarcinoma
6. Immunotherapy of advanced prostate cancer: A phase I/II trial using Mycobacterium vaccae (SRL172)
7. Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: Correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes
8. Reduction in cytokine production in colorectal cancer patients: Association with stage and reversal by resection
9. Loss of HLA class I expression in prostate cancer: Implications for immunotherapy
10. The 'bystander effect': Tumor regression when a fraction of the tumor mass is genetically modified
11. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component
12. In vivo analysis of the 'bystander effect': A cytokine cascade
13. A phase I study of recombinant adenovirus vector-mediated intraperitoneal delivery of herpes simplex virus thymidine kinase (HSV-TK) gene and intravenous ganciclovir for previously treated ovarian and extraovarian cancer patients
14. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: Results of a phase I clinical trial in malignant mesothelioma
15. In situ gene therapy for adenocarcinoma of the prostate: A phase I clinical trial
16. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice
17. Monitoring cancer by magnetic resonance
18. 31P-NMR investigation of solid tumours in the living rat
19. 31P-NMR studies of a human tumour in situ
20. 31P MRS of experimental tumours
21. Assessment of ganciclovir toxicity to experimental intracranial gliomas following recombinant adenoviral mediated transfer of the herpes simplex virus thymidine kinase gene by magnetic resonance imaging and proton spectroscopy
22. Long term rat survival after malignant brain-tumor regression by retroviral gene-therapy
23. Evaluation of the bystander effect in experimental brain tumors bearing herpes simplex virus-thymidine kinase gene by serial magnetic resonance imaging
24. 31P MRS evaluation of ganciclovir toxicity in C6 gliomas stably expressing the herpes simplex thymidine kinase gene
25. 1H MRS detects polyunsaturated fatty acid accumulation during gene therapy of glioma: Implications for the in vivo detection of apoptosis
26. Tumor immunogenicity is determined by the mechanism of cell death via induction of heat shock protein expression
27. Mycobacterium vaccae (SRL172): A potential immunological adjuvant evaluated in rat prostate cancer
28. Allogeneic whole tumour cell vaccination in the rat model of prostate cancer
29. Immunotherapy of prostate cancer in the Dunning rat model: Use of cytokine gene modified tumor vaccines
30. Demonstration of a rational strategy for human prostate cancer gene therapy
31. Prostate cancer gene therapy: Herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models
32. Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression
33. Targeted gene therapy for cancer: Herpes simplex virus thymidine kinase gene-mediated cell killing leads to anti-tumour immunity that can be augmented by co-expression of cytokines in the tumour cells
34. 31P NMR spectroscopic and near infrared spectrophotometric studies of effects of anesthetics on in vivo RIF-1 tumors. Relationship to tumor radiosensitivity
35. 31P nuclear magnetic resonance spectroscopy studies of the response of rat mammary tumours to endocrine therapy
36. Studies on human tumours by MRS: A review
37. Phospholipid metabolites as indicators of cancer cell function
38. Image-selected in vivo spectroscopy (ISIS). A new technique for spatially selective NMR spectroscopy
39. Accurate quantification of in vivo P-31 NMR signals using the variable projection method and prior knowledge